The mutational spectrum and molecular characteristics of acute myelomonocytic lineage leukemia, namely acute myeloid leukemia (AML) French-American-British (FAB) subtypes M4 and M5, are largely unknown. In order to explore the mutational spectrum and prognostic factors of FAB-M4 and -M5, next-generation sequencing (NGS) was performed to screen for mutated genes and fusion genes relevant to the pathogenesis of AML. Of the 63 patients enrolled in the study, 60% had more than three mutated genes. NPM1 had the highest mutation frequency, followed by DNMT3A, FLT3, NRAS, RUNX1, and TET2. Univariate analysis suggested that age ≥60 years was an independent factor for both poor event-free survival (EFS) and overall survival (OS, P = 0.009, 0.002, respectively), MYH11-CBFβ was associated with better EFS and OS (P = 0.029, 0.016, respectively). However, multivariate analysis was not able to identify any independent risk factor for survival in the cohort of FAB-M4 and -M5 patients, including peripheral white blood cell count, bone marrow blast percentage, MYH11-CBFβ, FLT3-ITD, mutations in NPM1 and DNMT3A, and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our study provided new insight into the mutational spectrum and molecular characteristics of FAB-M4 and -M5. The clinical implications of the genetic signature of FAB-M4 and -M5 need to be further elucidated by larger studies.
Introduction
The accumulation of somatic genetic changes in hematopoietic progenitor cells, including mutations, copy number alterations, and chromosomal translocations, is the core of acute myeloid leukemia (AML) pathogenesis [1] . Due to the profound clinical and biological heterogeneity of AML, accurate diagnosis and prognostic evaluation is essential for individualized treatment [2] . Next-generation sequencing (NGS) is characterized by massive parallel sequencing and high-throughput multiplex assay. It has been employed to depict mutational profiles [3] , characterize recurrent genetic mutations [4] of various diseases. In recent years, NGS has become an indispensable tool in AML research. With the help of NGS, a growing list of major mutations in AML leukaemogenesis has been identified, such as NPM1, FLT3, CEBPA, DNMT3A, IDH1/IDH2, EZH2, U2AF1, SMC1A, and SMC3 [5] . It also helped to demonstrate the complex interplay of genetic alterations in AML [6] .
Advances in identification of prognostic genetic alterations have facilitated greater detailed risk stratification [7, 8] . However, few studies have addressed the mutational spectrum of the French-American-British (FAB) subtypes M4 and M5, two unique subgroups of AML that exhibit monocytic morphology and cytochemical features [9] . In this study, we investigated the mutational signatures of FAB-M4 and -M5 and their prognostic value.
Patients and methods

Patients
Sixty-three AML patients derived from The Cancer Genome Atlas (TCGA) database (https://cancergenome.nih.gov/) were enrolled in this study [10] , including 41 FAB-M4 and 22 FAB-M5 patients. Written informed consent was obtained from each patient, and the study protocol was approved by Washington University Institutional Review Board. NGS was performed to evaluate the mutational spectrum of all patients. Detailed descriptions of clinical and molecular characteristics were publicly accessible from the TCGA website. Event-free survival (EFS) and overall survival (OS) were the primary endpoints of this study.
Next-generation sequencing and analysis
The procedure described by Mardis et al. [11] was followed for library construction and whole-genome sequencing. Briefly, Illumina DNA sequencing was used to generate between 58.5 and 155.9 billion base pairs of sequence data for each of the patients, with haploid coverages ranging from 18.9 to 50.4 billion base pairs. Heterozygous singlenucleotide polymorphism (SNP) detected in the wholegenome sequencing data was compared with SNP array genotypes, which confirmed bi-allelic detection of between 96.60 and 99.86% in all patients. Libraries for whole-exome sequencing were constructed and sequenced with either Illumina HiSeq 2000 or Illumina GAIIX using 76 bp pairedend reads. Standard quality control metrics, including error rates, percentage passing filter reads, and total Gb produced, were used to assess process performance before downstream analysis. The Illumina pipeline generated data files (BAM files) that contained the reads and the quality parameters. For each sample, reads were aligned using either Maq 0.6.8 or 0.7.1 or BWA 0.5.5 on a per-lane basis, merged into a single BAM file, and duplicate reads were removed using Picard 1.17, 1.22, or 1.25 (http://picard. sourceforge.net). We used the Mutational Significance in Cancer (MuSiC) package to categorize mutations, including AT transition, AT transversion, CG transition, CG transversion, CpG transition, CpG transversion, and indel. Statistical tests including convolution, Fisher's test, and a likelihood test were used to combine the category-specific binomials to obtain an overall P-value. Significantly mutated genes and pathways were identified with the above method.
Statistical analysis
The clinical and molecular characteristics of patients were summarized using descriptive statistics. Data sets were described with median and/or range. EFS was defined as the time from diagnosis to removal from the study due to relapse, death, or failure to achieve complete remission. OS was defined as the time from diagnosis to death from any cause, or was censored at the last follow-up. Survival was estimated using the Kaplan-Meier method and the log-rank test. Univariate Cox proportional hazards models were used to determine clinical and molecular variables associated with survival. Multivariate proportional hazards models were constructed for EFS and OS, using a limited backward elimination procedure. P < 0.05 was considered statistically significant for all analyses. All statistical tests were two sided and were performed by SPSS software 20.0 and GraphPad Prism software 5.0.
Results
Clinical and biological characteristics of patients
Clinical and biological characteristics of patients are summarized in Table 1 . Median age was 58 (range 21-81) years, with 29 cases older than 60 years. Thirty-four cases were men. Forty-one was FAB-M4 and 22 cases were FAB-M5. The median white blood cell (WBC) count at diagnosis was 27.1 × 10 9 /L, and in 29 cases it was ≥30 × 10 9 /L. Forty patients had a bone marrow blast percentage of more than 70% and 25 had peripheral blood blast more than 20%. Twenty-eight patients had abnormal karyotypes. Thirty-nine (61.9%) patients had intermediate-risk AML. Chemotherapy was differed in two patients due to old age and poor functional status. Twenty-four patients received hematopoietic stem cell transplantation (HSCT). Thirty-eight patients had more than three recurrent genetic mutations. NPM1 had the highest mutation frequency (n = 24, 38%), followed by DNMT3A (n = 23, 37%), FLT3-ITD/TKD (n = 20, 32%), NRAS (n = 7, 11%), RUNX1 (n = 6, 10%), and TET2 (n = 5, 8%) (Fig. 1) .
Comparison of EFS and OS between different clinical and molecular characteristic groups
EFS and OS of different age (≥60 vs. <60 years), WBC counts (≥30 vs. <30 × 10 9 /L), bone marrow blasts (≥70% vs. <70%), peripheral blasts (≥20% vs. <20%), number of Table 2 . Older patients (age ≥60 years) had shorter EFS and OS (P = 0.007, P = 0.001, respectively; Fig. 2a, b) . Presence of MYH11-CBFβ was associated with longer EFS and OS (P = 0.019, P = 0.009, respectively; Fig. 2c, d ). However, other variables had no effect on EFS and OS.
Evaluation of possible prognostic factors
Univariate analysis showed that age ≥60 years was an unfavorable factor for both EFS and OS (P = 0.009, P = 0.002, respectively), whereas MYH11-CBFβ fusion was a favorable factor for EFS and OS (P = 0.029, P = 0.016, respectively) (Table 3 ). However, in multivariate analysis, WBC counts, bone marrow blasts, MYH11-CBFβ fusion, FLT3-ITD, mutations in NPM1 and DNMT3A, and allogeneic HSCT did not show prognostic significance in our cohort of FAB-M4 and -M5 patients (Table 4) .
Discussion
The genetic heterogeneity and the complex interaction among different oncogenic pathways of AML has been well demonstrated in previous studies [12] . FAB-M4 and -M5 are unique subtypes of AML that belong to acute myelomonocytic lineage leukemia and their mutation spectrum has not been fully described. In our study, we found a high mutation frequency (≥10%) of NPM1, DNMT3A, FLT3 and NRAS. This was different from the results of other studies where CEBPA, NPM1, DNMT3A, FLT3, NRAS, IDH2 and WT1 were mutated in more than 10% of AML patients [13, 14] . Our results indicated that FAB-M4 and -M5 might have different mutational spectrum from other AML. Studies in cytogenetically normal AML had demonstrated that FLT3-ITD was associated with increased risk of relapse [15] while NPM1 was a good prognostic factor [16] . In our study, however, recurrent genetic mutations, including FLT3-ITD, NPM1, DNMT3A, NRAS/KRAS, IDH1/2, RUNX1, TET2, WT1, KIT, and U2AF1 [17, 18] , were not association with survival. The discrepancy could be related to the small sample size of our cohort, but could also be explained by possible interplay of mutated genes. Our results were consistent with previous findings that MYH11-CBFβ fusion indicated better survival [19] .
AML in older patients generally had poorer prognosis due to higher mutation burden, poorer baseline performance status, and co-morbidities [20] . In our cohort of FAB-M4 and -M5, age ≥60 years had a negative impact on survival. Of note, allogeneic HSCT (allo-HSCT), which was usually considered the cure for AML, did not show survival benefit in our study. High mutation frequency in NPM1, a good EFS event-free survival, OS overall survival, WBC white blood cell, BM bone marrow, PB peripheral blood, HSCT hematopoietic stem cell transplantation Fig. 1 The mutational spectrum of FAB-M4 and -M5 patients (n = 63). NPM1 had the highest mutation frequency (n = 24, 38%), followed by DNMT3A (n = 23, 37%), FLT3 (n = 20, 32%), NRAS (n = 7, 11%), RUNX1 (n = 6, 10%), and TET2 (n = 5, 8%). In addition, IDH2, IDH2, KRAS, WT1, KIT, and U2AF1 also had ≥5% mutation frequency prognostic factor as shown in other studies, could help explain the relatively benign course of FAB-M4 and -M5 that transplant was not mandatory to prevent relapse and prolong survival. To further clarify the benefit and risk of allo-HSCT in FAB-M4 and -M5 patients, larger prospective studies would be warranted. Several limitations need to be acknowledge. First, due to the limitation of sample size, we did not stratify data more precisely based on factors that affect the prognosis. Hence, our results did not fully account for the effect of mutational spectrum and clinical data on prognosis. Second, our study is a retrospective study, which is not as good as prospective research. Third, the prognostic significance of the related factors was the combination of chemotherapy and transplantation, it cannot reflect the effect of a single factor on the prognosis.
In conclusion, our study provided new insight into mutational spectrum and molecular signatures of FAB-M4 and -M5. These patients may not require allo-HSCT. More detailed mutational spectrum information and large prospective studies are required in the future for better prognostication of FAB-M4 and -M5. 
